Skip to Content

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

Nadia Harbeck, Director of the Breast Center, Dept. OB&GYN, LMU University Hospital, Munich, Germany, presented at ESMO the validation of endocrine therapy response rates and detailed analyses according to age subgroups focusing on premenopausal patients from ADAPT and the ongoing ADAPTcycle trial.

Nadia Harbeck

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top